1 |
Humira (adalimumab) |
CHO |
AbbVie |
10.659 billion |
Moderate to severe rheumatoid arthritis, moderate to severe chronic plaque psoriasis, moderate to severe Crohn’s disease; moderate to severe ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis |
2 |
Remicade (infliximab) |
Murine Myeloma |
Johnson & Johnson and Merck & Co. |
8.944 billion |
Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn’s Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines |
3 |
Rituxan (rituximab, MabThera) |
CHO |
Roche and Biogen Idec |
8.920 billion |
Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis |
4 |
Enbrel (etanercept) |
CHO |
Amgen and Pfizer |
8.325 billion |
Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis |
5 |
Lantus (insulin glargine) |
E.coli |
Sanofi |
7.849 billion |
Once daily treatment for diabetes |
6 |
Avastin (bevacizumab) |
CHO |
Roche |
7.037 billion |
Metastatic colorectal cancer (colon cancer), non–small cell lung cancer, glioblastoma & metastatic kidney |
7 |
Herceptin (trastuzumab) |
CHO |
Roche |
6.839 billion |
HER2-positive breast cancer and HER2-positive metastatic gastric cancer |
8 |
Neulasta (pegfilgrastim) |
E.coli |
Amgen |
4.392 billion |
Neutropenia caused by cancer chemotherapy |